KYNTHEUM APPROVED IN THE EU FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
Kyntheum is the first and only fully-human monoclonal antibody that selectively targets the IL-17 receptor subunit A on skin cells.
Kyntheum is the first and only fully-human monoclonal antibody that selectively targets the IL-17 receptor subunit A on skin cells.